Evaluation of the effectiveness of telemedical technologies in patients with digestive diseases

Cover Page


Cite item

Full Text

Abstract

BACKGROUND: The use of telemedical technologies (TMT) is widespread in providing care to patients of various profiles. However, TMTs are hardly ever used in gastroenterology, despite the extensive digitalization of healthcare. Potential sites for the use of TMTs among gastroenterological patients were assessed.

AIM: The study aimed to assess the effectiveness and benefits of TMTs in patients with digestive diseases.

  1. Patients with colorectal cancer (CRC): Screening and postoperative management. The TMT intervention increased the number of patients screened for CRC compared to standard face-to-face counseling. In addition, the quality of preparation for colonoscopy was higher in patients who interacted with the physician via TMTs compared to the control group. Most studies reported positive effects of TMTs on quality of life and physical activity in patients with CRC. However, the study by K. Beaver et al. showed that the incidence of CRC recurrence did not differ in the TMT and face-to-face groups.
  2. Patients with nonalcoholic fatty liver disease (NAFLD): Correction of lifestyle. When assessing the use of TMTs among NAFLD patients, a significant decrease in alanine aminotransferase and aspartate aminotransferase activity was found compared to that in face-to-face management. The results of the body mass index reduction are contradictory. The most pronounced tendency towards weight loss was observed with the telemedical follow-up of patients over a 6-month period.
  3. Patients with irritable bowel syndrome (IBS): Treatment and monitoring of symptoms. Two directions are distinguished in the treatment of IBS by ТМТs. The first is cognitive behavioral therapy (CBT). H. Everitt et al. showed clinically significant improvement in 72.8% of cases after 12 months of web-based CBT. The advantages of using telemedicine in the delivery of CBT include the geographical independence of the physician and the patient, personalization of treatment, and the possibility of ongoing support for the patient and his or her family. The second direction is the use of special diets, such as low-fermentable nutrient diets (FODMAP). Patients following the FODMAP diet supervised by the mobile app reduced symptom severity (odds ratio 55; 95% confidence interval 11–98, p=0.01). Special mobile apps (IBS Constant Care) were used to monitor the condition of patients with IBS, which analyze input data and assess severity, providing information to both the patient and the physician.
  4. Patients with inflammatory bowel disease (IBD): Patient training and telemonitoring. The study by L. Pang et al. proved that the patients’ quality of life in the telemedicine intervention group was significantly higher (p=0.03). Another advantage of using TMTs is the provision of access to educational materials about IBD and the possibility of remote contact with the treating physician. The patient’s ability to obtain necessary information reduces the need for unplanned visits to medical facilities, thus reducing the cost of organizing medical care for patients with IBD. The degree of IBD activity and risk of recurrence and adherence to therapy did not differ significantly between the telemedicine intervention group and the standard face-to-face follow-up group.

METHODS: A literature search relevant to the review was conducted in the PubMed database. The studies taken for assessment were those on the use of TMTs among patients with IBD, IBS, NAFLD, and CRC. TMTs were used to access educational information and dietary recommendations, provide information on lifestyle adjustments and physical activity, remind patients to take medicines, consult with physicians, and assess disease activity by completing online questionnaires. The various studies used text messaging, e-mail, mobile apps, websites, and videoconferencing apps as a means of communication.

RESULTS: The use of telemedicine in the management of patients with digestive diseases showed high efficiency. TMTs contribute to:

  • Improved quality of life in patients with digestive diseases.
  • Increasing physical activity of patients with CRC and NAFLD.
  • Improved quality of CRC screening.
  • Maintaining remission of IBD and CRC as effectively as face-to-face monitoring.

Moreover, the use of TMTs allows personalized treatment, ensures the ongoing support of the patient and his or her family by the medical staff, and provides patients with access to quality educational materials about the disease.

CONCLUSIONS: Thus, the use of TMTs is promising in the treatment of digestive diseases and requires wider introduction into practice.

Full Text

BACKGROUND: The use of telemedical technologies (TMT) is widespread in providing care to patients of various profiles. However, TMTs are hardly ever used in gastroenterology, despite the extensive digitalization of healthcare. Potential sites for the use of TMTs among gastroenterological patients were assessed.

AIM: The study aimed to assess the effectiveness and benefits of TMTs in patients with digestive diseases.

  1. Patients with colorectal cancer (CRC): Screening and postoperative management. The TMT intervention increased the number of patients screened for CRC compared to standard face-to-face counseling. In addition, the quality of preparation for colonoscopy was higher in patients who interacted with the physician via TMTs compared to the control group. Most studies reported positive effects of TMTs on quality of life and physical activity in patients with CRC. However, the study by K. Beaver et al. showed that the incidence of CRC recurrence did not differ in the TMT and face-to-face groups.
  2. Patients with nonalcoholic fatty liver disease (NAFLD): Correction of lifestyle. When assessing the use of TMTs among NAFLD patients, a significant decrease in alanine aminotransferase and aspartate aminotransferase activity was found compared to that in face-to-face management. The results of the body mass index reduction are contradictory. The most pronounced tendency towards weight loss was observed with the telemedical follow-up of patients over a 6-month period.
  3. Patients with irritable bowel syndrome (IBS): Treatment and monitoring of symptoms. Two directions are distinguished in the treatment of IBS by ТМТs. The first is cognitive behavioral therapy (CBT). H. Everitt et al. showed clinically significant improvement in 72.8% of cases after 12 months of web-based CBT. The advantages of using telemedicine in the delivery of CBT include the geographical independence of the physician and the patient, personalization of treatment, and the possibility of ongoing support for the patient and his or her family. The second direction is the use of special diets, such as low-fermentable nutrient diets (FODMAP). Patients following the FODMAP diet supervised by the mobile app reduced symptom severity (odds ratio 55; 95% confidence interval 11–98, p=0.01). Special mobile apps (IBS Constant Care) were used to monitor the condition of patients with IBS, which analyze input data and assess severity, providing information to both the patient and the physician.
  4. Patients with inflammatory bowel disease (IBD): Patient training and telemonitoring. The study by L. Pang et al. proved that the patients’ quality of life in the telemedicine intervention group was significantly higher (p=0.03). Another advantage of using TMTs is the provision of access to educational materials about IBD and the possibility of remote contact with the treating physician. The patient’s ability to obtain necessary information reduces the need for unplanned visits to medical facilities, thus reducing the cost of organizing medical care for patients with IBD. The degree of IBD activity and risk of recurrence and adherence to therapy did not differ significantly between the telemedicine intervention group and the standard face-to-face follow-up group.

METHODS: A literature search relevant to the review was conducted in the PubMed database. The studies taken for assessment were those on the use of TMTs among patients with IBD, IBS, NAFLD, and CRC. TMTs were used to access educational information and dietary recommendations, provide information on lifestyle adjustments and physical activity, remind patients to take medicines, consult with physicians, and assess disease activity by completing online questionnaires. The various studies used text messaging, e-mail, mobile apps, websites, and videoconferencing apps as a means of communication.

RESULTS: The use of telemedicine in the management of patients with digestive diseases showed high efficiency. TMTs contribute to:

  • Improved quality of life in patients with digestive diseases.
  • Increasing physical activity of patients with CRC and NAFLD.
  • Improved quality of CRC screening.
  • Maintaining remission of IBD and CRC as effectively as face-to-face monitoring.

Moreover, the use of TMTs allows personalized treatment, ensures the ongoing support of the patient and his or her family by the medical staff, and provides patients with access to quality educational materials about the disease.

CONCLUSIONS: Thus, the use of TMTs is promising in the treatment of digestive diseases and requires wider introduction into practice.

×

About the authors

Yuliya A. Gazizova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Author for correspondence.
Email: juliagazizova98@gmail.com
ORCID iD: 0000-0002-6742-3898
Russian Federation, Moscow

Donier S. Bakirkhanov

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: donier00@gmail.com
ORCID iD: 0000-0003-1037-3700
Russian Federation, Moscow

Tamara S. Nefedova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: prosto.toma.22@gmail.com
ORCID iD: 0000-0002-6718-8701
Russian Federation, Moscow

Nina V. Kostikova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: n.kostikowa@yandex.ru
ORCID iD: 0000-0003-3509-7271
Russian Federation, Moscow

Dina A. Akhmedzyanova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department

Email: dina_akhm@mail.ru
ORCID iD: 0000-0001-7705-9754
Russian Federation, Moscow; Moscow

Olga V. Tashchyan

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: tashchyan_o_v@staff.sechenov.ru
ORCID iD: 0000-0001-6759-6820
Russian Federation, Moscow

Yuliya F. Shumskaya

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department

Email: ashe.danny.jush@gmail.com
ORCID iD: 0000-0002-8521-4045
Russian Federation, Moscow; Moscow

Marina G. Mnatsakanyan

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: mnatsakanyan08@mail.ru
ORCID iD: 0000-0001-9337-7453
Russian Federation, Moscow

References

  1. McDonnell ME. Telemedicine in Complex Diabetes Management. Curr Diab Rep. 2018;18(7):42. doi: 10.1007/s11892-018-1015-3
  2. Alvarez P, Sianis A, Brown J, Ali A, Briasoulis A. Chronic disease management in heart failure: focus on telemedicine and remote monitoring. Rev Cardiovasc Med. 2021;22(2):403–413. doi: 10.31083/j.rcm2202046
  3. Timpel P, Oswald S, Schwarz PEH, Harst L. Mapping the Evidence on the Effectiveness of Telemedicine Interventions in Diabetes, Dyslipidemia, and Hypertension: An Umbrella Review of Systematic Reviews and Meta-Analyses. J Med Internet Res. 2020;22(3):e16791. doi: 10.2196/16791
  4. Barbosa MT, Sousa CS, Morais-Almeida M, Simões MJ, Mendes P. Telemedicine in COPD: An Overview by Topics. COPD. 2020;17(5):601–617. doi: 10.1080/15412555.2020.1815182
  5. Elepaño A, Fusingan AS, Yasay E, Sahagun JA. Mobile health interventions for improving colorectal cancer screening rates: A systematic review and meta-analysis. Asian Pac J Cancer Prev. 2021;22(10):3093–3099. doi: 10.31557/APJCP.2021.22.10.3093
  6. El Bizri M, El Sheikh M, Lee GE, Sewitch MJ. Mobile health technologies supporting colonoscopy preparation: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2021;16(3):e0248679. doi: 10.1371/journal.pone.0248679
  7. Ayyoubzadeh SM, R Niakan Kalhori S, Shirkhoda M, Mohammadzadeh N, Esmaeili M. Supporting colorectal cancer survivors using eHealth: a systematic review and framework suggestion. Support Care Cancer. 2020;28(8):3543–3555. doi: 10.1007/s00520-020-05372-6
  8. Beaver K, Campbell M, Williamson S, et al. An exploratory randomized controlled trial comparing telephone and hospital follow-up after treatment for colorectal cancer. Colorectal Dis. 2012;14(10):1201–1209. doi: 10.1111/j.1463-1318.2012.02936.x
  9. Saokaew S, Kanchanasurakit S, Kositamongkol C, et al. Effects of Telemedicine on Obese Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021;8:723790. doi: 10.3389/fmed.2021.723790
  10. Kwon OY, Choi JY, Jang Y. The Effectiveness of eHealth Interventions on Lifestyle Modification in Patients With Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-analysis. J Med Internet Res. 2023;25:e37487. doi: 10.2196/37487
  11. Everitt HA, Landau S, O’Reilly G, et al. Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial. Lancet Gastroenterol Hepatol. 2019;4(11):863–872. doi: 10.1016/S2468-1253(19)30243-2
  12. Ankersen DV, Weimers P, Bennedsen M, et al. Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial. J Med Internet Res. 2021;23(12):e30291. doi: 10.2196/30291
  13. Pedersen N, Andersen NN, Végh Z, et al. Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol. 2014;20(43):16215–16226. doi: 10.3748/wjg.v20.i43.16215
  14. Pang L, Liu H, Liu Z, et al. Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Med Internet Res. 2022;24(3):e28978. doi: 10.2196/28978
  15. Davis SP, Ross MSH, Adatorwovor R, Wei H. Telehealth and mobile health interventions in adults with inflammatory bowel disease: A mixed-methods systematic review. Res Nurs Health. 2021;44(1):155–172. doi: 10.1002/nur.22091
  16. Fiorino G, Allocca M, Chaparro M, et al. ‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2019;13(1):127–137. doi: 10.1093/ecco-jcc/jjy140
  17. Nguyen NH, Martinez I, Atreja A, et al. Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review. Am J Gastroenterol. 2022;117(1):78–97. doi: 10.14309/ajg.0000000000001545

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 79539 от 09 ноября 2020 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies